Valo Therapeutics Announces Acquisition Of Bruker Corporation’S Latest Mass Spectrometer Platform For Tumor Antigen Identification With Valotx’S Peptichip Technology
Valo Therapeutics Announces Acquisition Of Bruker Corporation’S Latest Mass Spectrometer Platform For Tumor Antigen Identification With Valotx’S Peptichip Technology
10/10/23, 7:03 AM
Location
helsinki
Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer, announces it is the first biotech company in Europe to install and use the Bruker Corporation’s new timsTOF Ultra mass spectrometer and liquid chromatography platform, which provides transformative speed and sensitivity for antigen identification in connection with ValoTx’s PeptiCHIP technology.
Company Info
Location
Helsinki, Etelä-Suomi, Finland
Company info
Valo Therapeutics (ValoTx) is a developer of novel immunotherapies in cancer and infectious disease. Our unique approach to immunotherapy, based on oncolytic viruses and viral vectors combined with disease-specific peptides, delivers highly adaptable and immunogenic therapeutic vaccination platforms. A spin-out company from the University of Helsinki, Finland, Valo Tx has assembled a talented team of immunotherapy experts, who together with the founding scientists have the necessary expertise to take its patented technology through clinical development and make it available to patients. The management team has a proven track record of developing successful companies from a laboratory idea to a full stock exchange listing.